Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors

Laura S. Wood, Harvey Lemont, Aminah Jatoi, Mario E. Lacouture, Caroline Robert, Karen Keating, Roger Anderson

    Research output: Contribution to journalArticlepeer-review

    22 Citations (Scopus)

    Abstract

    Multikinase inhibitors (MKIs, eg, sorafenib and sunitinib) are oral anticancer agents associated with handfoot skin reaction (HFSR), a cutaneous adverse event affecting 20%-40% of patients treated with these drugs. Although usually mild, symptoms of HFSR can evolve into a painful condition, resulting in a shortened duration or intensity of cancer treatment. An international, interdisciplinary panel of experts recently provided the first consensus recommendations for the management of MKI-associated HFSR.

    Original languageEnglish
    Pages (from-to)23-29
    Number of pages7
    JournalCommunity Oncology
    Volume7
    Issue number1
    DOIs
    Publication statusPublished - 1 Jan 2010

    Cite this